A- A A+

Ho, Hsiang-Ling (何祥齡)

Ho, Hsiang-Ling(何祥齡)

簡介

學歷
  1. 陽明大學 醫學生物技術暨檢驗學系 學士
  2. 陽明大學 生化暨分子生物研究所 博士
經歷 現職:
  1. - 迄今 臺北榮民總醫院病理檢驗部 一般檢驗科 主任
  2. - 迄今 國立陽明交通大學 醫學生物技術暨檢驗學系 兼任助理教授
  3. - 迄今 台灣醫事檢驗學會 理事
  4. - 迄今 中華民國醫事檢驗師公會全國聯合會 理事
經歷:
  1. - 臺北榮總病理檢驗部 分子病理科 技師
  2. - 臺北榮總病理檢驗部 外科病理科 醫事檢驗師
  3. - 臺北榮總病理檢驗部 博士後研究員
  4. - 中央研究院生醫所 博士後研究員
醫療專長
  1. 分子生物
  2. 生物醫學檢驗
  3. 實驗室品質管理
證照
  1. 衛生福利部 醫事檢驗師證書 (檢字第 012059號)
  2. 臺灣醫事檢驗學會分子領域專門醫事檢驗師證書 (醫檢分字第0025號)
語言專長
  1. 國語、台語、英語

著作

  1. Yeh YC, Ho HL, Wu YC, Pan CC, Wang YC, Chou TY. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma.Mod Pathol. doi:10.1038/s41379-019-0357-y, 2019
  2. Ho HL, Kao HL, Yeh YC, Chou TY. The Importance of EGFR Mutation Testing in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed from Small Lung Biopsies. Diagn Pathol. 14(1):59, 2019
  3. Ho HL, Chou TY, Yang SH, Jiang JK, Chen WS, Chao Y, Teng HW. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. J Cancer Res Clin Oncol. 145(7):1785-1794, 2019
  4. Chang WC, Yeh YC, Ho HL, Hsieh SL, Chou TY. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Am J Clin Pathol. pii: aqz035. doi: 10.1093/ajcp/aqz035, 2019
  5. Lin CS, Huang YY, Pan SC, Cheng CT, Liu CC, Shih CH, Ho HL, Yeh YC, Chou TY, Lee MY, Wei YH. Involvement of increased p53 expression in the decrease of mitochondrial DNA copy number and increase of SUVmax of FDG-PET scan in esophageal squamous cell carcinoma.Mitochondrion. 47:54-63, 2019
  6. Ho HL, Huang CC, Ku WH, Ho CL, Lin CH, Yu SL, Chou TY. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.. J Chin Med Assoc. 82(6):473-476, 2019
  7. Yeh YC, Kao HL, Lee KL,Wu MH, Ho HL, Chou TY. Epstein-Barr Virus-associated Pulmonary Carcinoma: Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung. Am J Surg Pathol. 43:211–219, 2019
  8. Lin YC, Lin CH, Yeh YC, Ho HL, Wu YC, Chen MY, Chou TY. High O-linked N-acetylglucosamine transferase expression predicts poor survival in patients with early stage lung adenocarcinoma. Oncotarget. 9(57):31032-31044, 2018
  9. Chen YY, Ho HL, Lin SC, Hsu CY, Ho DM. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Neurosurgery. doi: 10.1093/neuros/nyy338, 2018
  10. Chen YY, Ho HL, Lin SC, Ho TD, Hsu CY. Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients. Am J Clin Pathol. 149(5):412-417, 2018
  11. Tseng YH1, Ho HL, Lai CR, Luo YH, Tseng YC, Whang-Peng J, Lin YH, Chou TY, Chen YM. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. J Thorac Oncol. 13(3):447-453, 2018
  12. Chiang CL, Wang LC, Ho HL, Tsai CM, Yeh YC, Hsu WH, Chou TY, Chiu CH, Wu YC. Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. Oncotarget. 9(4):5435-5444, 2017
  13. Hsu CY, Ho HL, Lin SC, Ho TD, Ho DM. The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma. PLoS One. 12(10):e0186430, 2017
  14. Yeh YC, Lei HJ, Chen MH, Ho HL, Chiu LY, Li CP, Wang YC. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated with Better Prognosis. Am J Surg Pathol. 41(12):1630-41, 2017
  15. Yang CF, Ho HL, Lin SC, Hsu CY, Ho DM. Detection of human cytomegalovirus in glioblastoma among Taiwanese subjects. PLoS One. 12(6):e0179366, 2017
  16. Kao HL, Yeh YC, Lin CH, Hsu WF, Hsieh WY, Ho HL*, Chou TY*. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods. (* Co-corresponding authors) Lung Cancer. 101: 40-47, 2016
  17. Hsu CY, Ho HL, Lin SC, Chen MH, Hsu SP, Yen YS, Guo WY, Ho DM. Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients. Appl Immunohistochem Mol Morphol. 25(7):497-504, 2017
  18. Kao HL, Lai CR, Ho HL, Pan CC. Molecular typing for detection of high-risk human papillomavirus is a useful tool for distinguishing primary bladder carcinoma from secondary involvement of uterine cervical carcinoma in the urinary bladder. Histopathology. 68(4):513-9, 2016
  19. Chiu CH*, Ho HL*, Doong H, Yeh YC, Chen MY, Chou TY, Tsai CM. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. (* co-first author) Oncotarget. 6(10):8407-17, 2015
  20. Hsu CY, Ho HL, Lin SC, Chang-Chien YC, Chen MH, Hsu SP, Yen YS, Guo WY, Ho DM.Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. J Neuro-oncol. 122(1):179-88, 2015
  21. Hsu CY, Ho HL, Chang-Chien YC, Chang YW, Ho DM.MGMT promoter methylation in non-neoplastic brain. J Neuro-oncol. 121(3):459-67, 2015
  22. Chiu CH*, Ho HL*, Chiang CL, Lin SF, Ma HH, Chuang YT, Lin KY, Tsai CM, Chou TY. Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays. (* co-first author) J Thorac Oncol. 9(1):91-6, 2014
  23. Hsu CY, Yang CF, Liao LR, Ho HL, Ho DM. Tonsil surface epithelium is ideal for monitoring Ki-67 immunohistochemical staining. Histopathology. (6):810-6, 2013
  24. Ho HL, Chang FP, Ma HH, Liao LR, Chuang YT, Chang-Chien YC, Lin KY, Chou TY. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods.Respirology. (8):1261-70, 2013
  25. Luo YH, Ho HL, Tsai CM, Shih JF, Chiu CH, Lai SL, Lee YC, Perng RP, Whang-Peng J, Chou TY, Chen YM. The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. Am J Clin Oncol. 38(2):147-151, 2015 
  26. Hsu CY, Lin SC, Ho HL, Chang-Chien YC, Hsu SP, Yen YS, Chen MH, Guo WY, Ho DM. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Am J Surg Pathol. 37(2):264-271, 2013
  27. Ho HL, Lee HY, Liao HC, Chen MY. Involvement of Saccharomyces cerevisiae Avo3p/Tsc11p in maintaining TOR complex 2 integrity and coupling to downstream signaling. Eukaryot Cell. 7(8):1328-1343, 2008
  28. Ho HL, Shiau YS, Chen MY. Saccharomyces cerevisiaeTSC11/AVO3 participates in regulating cell integrity and functionally interacts with components of the Tor2 complex. Curr Genet. 47(5):273-88, 2005